barium sulfate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
barium sulfate: clinical details
Prescribing considerations
- Diagnostic use under appropriately trained medical supervision only.
- Assess aspiration risk, swallowing integrity, gastrointestinal stenosis and factors increasing perforation risk.
- Review asthma, atopy, previous contrast reactions and relevant excipient sensitivities.
- Consider dehydration, constipation, impaired gastrointestinal motility, renal impairment, cardiac disease and controlled-sodium requirements.
- Ensure appropriate hydration and provide aftercare advice about bowel clearance.
Contraindications and cautions
- Hypersensitivity to barium sulfate or an excipient.
- Known or suspected gastrointestinal perforation, tracheo-oesophageal fistula, gastrointestinal haemorrhage or ischaemia.
- Megacolon or toxic megacolon, necrotising enterocolitis or severe ileus.
- Infants with swallowing disorders.
- Immediate use following gastrointestinal surgery or specified invasive gastrointestinal procedures.
- Use during or within four weeks after rectal or prostate radiotherapy, or with new gastrointestinal injury or chemical burns.
- Hereditary fructose intolerance because the selected product contains sorbitol.
Monitoring
- Observe during administration for aspiration and hypersensitivity.
- Stop administration immediately if material enters the larynx.
- Assess sudden collapse or acute illness during or after the procedure for serious procedural complications.
- Monitor bowel passage, hydration and symptoms suggesting impaction, obstruction or perforation.
Clinical pharmacology
Barium sulfate is an inert radiopaque agent without pharmacological activity. It passes through the gastrointestinal tract largely unchanged, and systemic absorption is pharmacologically insignificant.
Formulation and product differences
- The selected product is a high-density powder for oral suspension intended for double-contrast X-ray examination of the upper gastrointestinal tract.
- It must be reconstituted before administration and used promptly after preparation.
- It contains sorbitol, sodium, sweeteners, suspending agents and fruit flavourings, which may affect suitability for some patients.
barium sulfate interactions
No formal interaction studies have been performed, but material remaining in the gastrointestinal tract can have practical consequences.
Other oral medicines
Barium sulfate formulations may alter their absorption, so the radiology team may advise separating administration.
Other gastrointestinal contrast agents
Residual barium may interfere with subsequent imaging of the same gastrointestinal area for several days.
Oral products containing sorbitol or fructose
Combined sorbitol or fructose exposure may increase gastrointestinal effects.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.